Medicalgorithmics S.A. — Regulatory Filings 2026

Apr 1, 2026

Report Content Subject: Medicalgorithmics S.A. receives an order worth PLN 654 thousandin connection with the conclusion of the annex

Current report no.: 10/2026

Date of preparation: 1 April 2026

Legal basis: Article 17(1) of the MAR Regulation - confidentialinformation.

The Management Board of Medicalgorithmics S.A. (the "Company","Medicalgorithmics") announces that on March 31st 2026 the Companyentered into an annex to the agreement (the "Agreement") with a partnerfrom Israel (the "Contractor"), extending the scope of the existingcooperation with new products and introducing further significantchanges to the Agreement concerning, among others, payment terms, andprice.

Under the amended Agreement, Medicalgorithmics will additionally providethe Contractor with the DeepRhythmPlatform (DRP) software using DRAIalgorithms to analyze and classify ECG signals and a software solutionfor autonomous assessment of coronary artery disease (CAD) - VCAST ("ECGSoftware") together with the right to use under the Agreement. Inaddition, Medicalgorithmics granted the Contractor the exclusive rightto sell, market and distribute the Product (Pocket ECG and Kardiobeat.aidevices) for the purpose of diagnostics in Israel and West Bank _Palestine. The exclusivity provisions do not apply to entities operatingin multiple international markets or to non-commercial clinicaltrial-related collaborations.

In accordance with the terms of the Agreement, for the Product andrelated services provided by the Company to the Contractor, includingthe ECG Software, the Contractor shall pay remuneration (specified inEUR) for the devices (according to the unit price) and for each month ofuse of the ECG Software according to monthly flat fees for monitoring oraccording to the unit price per examination (the price depends on thetype of ECG Software). In addition, the Parties have agreed onindividual terms and conditions with respect to the entity indicated inthe Agreement and an individual price annex with regard to DRP softwareand Kardiobeat.ai devices. Pursuant to the Agreement, the Parties haveagreed on the terms of the order for Kardiobeat.ai devices, which willbe accepted for execution by the Company after the Contractor has made a100% prepayment for the order. The remaining provisions of the annex donot differ from the practices commonly used on the market for this typeof products and services. The Management Board informs that the Companyhas received an order from the Contractor for Kardiobeat.ai devicesbased on the new business arrangements contained in the annex. The valueof the remuneration for the order will amount to PLN 654 thousand in2026.

The execution of the Agreement (annex) constitutes a significant step inthe implementation of the Company's strategy, as presented in currentreport No. 16/2023 dated 19 June 2023, which aims to substantiallyincrease the Company's revenues and profitability and to generatepositive cash flows. In the Management Board's opinion, the execution ofthe Agreement will strengthen the Company's market position, open up newgrowth opportunities in the Israeli market and, consequently, have apositive impact on its financial results in the coming periods.

The values in EUR indicated in this report have been converted into PLNaccording to the exchange rate 4.29 EUR/PLN.